Bruker is a performace leader in preclinical imaging instrumentation. Bruker offers nine imaging modalities: PET, SPECT, CT, MRI, MPI, fluorescence, luminiscence, radioisotipic imaging and X-ray.
Accelerate to discover
Related topics
Vizgen webinar: spatial relationships in Developmental Biology
Nov 21, 2023
MERFISH integrates spatial transcriptomics technology with high resolution spatial imaging, In this webinar we will...
Nov 14, 2023
The xCELLigence RTCA eSight enables simultaneous real time biosensor impedance-based and...
NanoCellect webinar: Plant Potential - Gentle Cell Sorting for Enhanced Plant Biology Workflows
Nov 3, 2023
Gentle cell sorting is a useful tool to increase the efficiency of plant biology workflows that include gene...
Single Cell Deposition: the cornerstone of Flow Cytometry for cellular analysis and manipulation
Nov 2, 2023
One notable technology for harnessing the power of single cell deposition is the NanoCellect WOLF G2 Cell Sorter and N1...
Emulate in vivo conditions – introduce shear flow to your experiments with BioFlux system
Oct 31, 2023
Most research is still conducted in vitro without the presence of flow. We use the BioFlux System to give you the...
Single Cell Deposition: the cornerstone of Flow Cytometry for cellular analysis and manipulation
Oct 30, 2023
One notable technology for harnessing the power of single cell deposition is the NanoCellect WOLF G2 Cell Sorter and N1...
Validation of an orthotopic non-small cell lung cancer mouse model to use in radiotherapy studies
Oct 30, 2023
The use of pre-clinical orthotopic mouse models is essential for the development of novel therapies targeting solid...
Atypical Teratoid Rhabdoid Tumours Are Susceptible to Panobinostat-Mediated Differentiation Therapy
Oct 20, 2023
To assess tumour growth, mice were imaged using the AMI-HTX bioluminescent imaging system (Spectral Instruments...
Jun 13, 2017
Pancreatic cancer has a remarkably high mortality rate, primarily due to late detection of the disease (Siegel et al. 2016). Therefore, efforts to reduce the incidence of pancreatic cancer may provide significant benefit in people at risk of developing the disease. Obese and diabetic individuals are known to have an increased risk of pancreatic cancer (Bardeesy et al. 2002).
Therefore, this study sought to determine whether aspartame or stevia, two commonly used artificial sweeteners, provide benefit in mice with pancreatic cancer. Lead author Dr. James Dooley and colleagues at the University of Leuven in Belgium published their paper entitled, “No Effect of Dietary Aspartame or Stevia on Pancreatic Acinar Carcinoma Development, Growth, or Induced Mortality in a Murine Model,” in Frontiers of Oncology in February of 2017.
The role of artificial sweeteners in cancer risk remains controversial (Tandel 2011), with some studies proposing anti-tumor effects while others purport carcinogenic properties of these chemicals. “With strong links to diabetes, glucose consumption and obesity, pancreatic cancer remains one of the strongest candidates to detect an oncogenic role, either promoting or suppressive, of artificial sweeteners,” the authors begin.
In order to test the potential role of these artificial sweeteners in pancreatic cancer disease progression, the authors allowed mice to drink water with or without aspartame or stevia present. The researchers used a Bruker Biospin 9.4 T Biospec small animal MR scanner to perform magnetic resonance imaging (MRI) in order to locate tumors in the mice and follow their progression over time.
Related technologies: Magnetic resonance imaging
Get more info
Brand profile
Bruker is a performace leader in preclinical imaging instrumentation. Bruker offers nine imaging modalities: PET, SPECT, CT, MRI, MPI, fluorescence, luminiscence, radioisotipic imaging and X-ray.
More info at:
www.bruker.com